Skip to content
SERB Pharmaceuticals
-
SERB Pharmaceuticals acquires rights to Idefirix in US$133.6M deal with Hansa Biopharma
Idefirix is a first-in-class treatment designed to help highly sensitised adult kidney transplant patients who face difficulties finding compatible donors.